{
  "_id": "5ba9748f973083c5dc441e994057e06a1230d3e4d7e935e74258c7bffb3ed280",
  "feed": "market-watch",
  "title": "Amgen Q1 revenue beats expectations, profit declines; Revenue rises to more than $6 billion",
  "text": "<p>Revenue rose to $6.23 billion from $5.9 billion. The company said the higher revenue stemmed from 2% growth in global product sales and increased other revenue from its Covid-19 antibody manufacturing collaboration. Analysts polled by FactSet expected $6.07 billion.</p><p>Earlier Wednesday, Amgen reported top-line results from two Repatha studies. It said both studies showed Repatha was safe and well-tolerated when administered at 140 milligrams every two weeks or 420 milligrams monthly. The company said study results will be shared with regulatory authorities.</p><p>The company said the studies were designed to assess the long-term safety and tolerability of Repatha over five years in adults with clinically evident atherosclerotic cardiovascular disease.</p><p>Write to Denny Jacob at denny.jacob@wsj.com</p><p>Amgen Q1 revenue beats expectations, profit declines</p>",
  "published": "2022-04-27T21:03:00.000Z",
  "tags": [
    {
      "id": "US0311621009",
      "nexusId": "10036019",
      "name": "Amgen Inc.",
      "offsets": [
        {
          "start": 798,
          "end": 803
        },
        {
          "start": 0,
          "end": 5
        },
        {
          "start": 286,
          "end": 291
        }
      ]
    }
  ]
}